Company intelligence / Profile preview

Xenthera

Salt Lake City, Utah, United Statesxenthera.com ↗

Ownership: Private
Development stage: Other

Overview

Xenthera’s lead candidate, XT-0528, is an oral small molecule RORγT inverse agonist. It has completed three Phase I trials in healthy volunteers with minimal safety issues and demonstrated reduction of the target biomarker IL‑17 across dose ranges. A new Phase I trial in patients with advanced recurrent or metastatic solid tumors has been initiated. Preclinical data show that RORγT inhibition limits tumor growth in cellular and mouse models of pancreatic cancer and may reduce immune-oncology therapy toxicity by modulating inflammatory signaling[1][3][7].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharmaceutical partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Xenthera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xenthera.

Explore the full profile